#United States #New York #Class Action #Pomerantz LLP #Cassava Sciences

Pomerantz LLP, a well-established law firm known for its expertise in class action lawsuits, has recently notified shareholders of Cassava Sciences, Inc. about a pending legal action. The class action lawsuit has been initiated due to concerns regarding allegations of securities fraud and other potentially unlawful business practices within the company. Investors who have suffered losses from their investments are encouraged to take note of this critical update, as they may have the option to join the class action case. The firm is currently seeking to connect with investors who purchased or acquired Cassava shares during a specified Class Period. This period refers to the timeframe during which the company may have made misleading statements or failed to disclose essential information that significantly affected the stock's value. Those affected are urged to reach out to Pomerantz LLP promptly to ensure they meet the necessary deadlines for participation in the lawsuit. To provide a brief context, Cassava Sciences, Inc. faced a significant downturn in its stock value following disappointing news regarding its Alzheimer's drug, simufilam. On November 25, 2024, the company announced that the drug had failed to meet critical endpoints in a Phase 3 clinical trial, which resulted in a staggering 83.78% drop in its stock price, settling at $4.30 per share. This marked a pivotal moment for not only the company but also for its investors who saw substantial losses as a result. Pomerantz LLP emphasizes that potential plaintiffs must act swiftly. The firm has established a deadline of February 10, 2025, for affected shareholders to notify the court of their intention to be appointed as Lead Plaintiff in this class action lawsuit. Interested investors can reach out to attorney Danielle Peyton via email or telephone for further assistance and guidance on how to proceed. It's also advisable for those inquiring through email to include their mailing addresses and the number of shares they purchased, as this information will be crucial for processing their claims. The firm, with offices located in major cities around the world, has built a strong reputation over its 85-year history in championing the rights of investors against corporate wrongdoings and securities fraud. Pomerantz has successfully recovered billions in damages on behalf of class members, reinforcing its status as a leader in this field. Investors who feel misled by the company are encouraged to act quickly and seek legal advice, as joining a class action can often be an effective way to hold companies accountable for their actions. Prospective investors seeking more detailed information about the lawsuit, including a copy of the complaint, can visit the official Pomerantz website. The firm continues its mission to pursue justice for those harmed by corporate misconduct, and as such, playing an active role in legal proceedings can often empower shareholders to take a stand against perceived injustices. Continued vigilance in the market context is advised, and shareholders are encouraged to remain informed about their rights and options moving forward in these possibly challenging financial circumstances.